Back to the A-share market
On 22 September, per the CSRC website, Shenzhen Jingfeng Medical Technology signed a tutoring agreement with CITIC Securities to start A-share listing tutoring. On 11 September Jingfeng announced its plan to list A-shares and issue renminbi ordinary shares. The tutoring runs September 2026 to January 2027, covering governance, compliance, financial controls and internal risk, toward acceptance. Notably, this starts only eight months after its Hong Kong main-board debut.
In January Jingfeng listed on the Hong Kong main board with a luxury cornerstone set: Abu Dhabi Investment Authority, UBS Asset Management, Tencent and ChinaAMC, with cornerstone subscriptions of USD 75 million. It issued 27.72 million H shares and raised HK$1.379 billion, used mainly for single-port laparoscopic robot R&D, capacity expansion, product iteration and pipeline. On listing day it closed at HK$56.6, about HK$22.8 billion market value. It now trades at HK$37.1, about HK$14.55 billion, down about 36.6 per cent from day one.
From a prototype to a platform
In 2013 the domestic “Miaoshou” surgical-robot prototype succeeded and won approval in 2021, filling a domestic blank. Professor Wang Shuxin, a pioneer of Chinese surgical robotics, took part. Four years later his students Wang Jianchen and Gao Yuanqian founded Jingfeng, focused on core surgical-robot technology, and became China’s first and the world’s second firm with approvals for multi-port, single-port and natural-orifice robots. A 265-person cross-disciplinary R&D team built a platform on seven proprietary core modules, with over 700 patent applications, top in China.
In July 2026 Jingfeng strategically invested in Yuanhao Dynamics, an AI firm focused on multimodal 4D world models, to deepen AI-robot fusion and explore embodied surgical platforms. Its three-in-one solution covers multi-port, single-port and remote surgery, with products approved in Britain, New Zealand, Saudi Arabia and Australia. In March 2026 its three-in-one platform won National Medical Products Administration approval, the world’s first and only integrated multi-port, single-port and remote surgical platform.
Commercial traction
Since commercialisation began in December 2022, Jingfeng sold 20 multi-port laparoscopic robots in 2024, ranking first among domestic makers. In 2025 it completed a remote surgery across 12,035 kilometres with 199-millisecond latency, a Guinness record. By 30 June 2026 its multi-port robots passed 18,300 procedures, single-port over 3,300, and its cloud remote system over 700 remote surgeries. Zhujiang Hospital alone passed 1,700 robot-assisted procedures.
Jingfeng covers 18 Chinese provinces and reaches Europe, Asia-Pacific, the Middle East, Africa and South America, with 158 units installed and delivered globally by mid-2026. Its first post-listing half-year report shows first-half 2026 revenue of RMB 319 million, up 113.8 per cent, driven by overseas multi-port sales. Gross margin rose from 62.8 to 64.1 per cent, and the loss narrowed 78.4 per cent to RMB 19.25 million, a clear operating turning point.
The A-share return strengthens its domestic brand, opens the onshore capital channel and accelerates commercialisation and iteration. The long-term space is worth watching.
Editor’s note: This is an adapted translation of the original OFweek Robotics report. It has been trimmed and restructured for readability for an international business audience. The full original (in Chinese) is at https://robot.ofweek.com/2026-09/ART-8321203-8120-30704496.html.